26May 2017

SERUM LIPID PROFILE AND MAGNESIUM LEVEL IN THE HYPOGLYCEMIC TYPE II DIABETIC SUBJECTS.

  • Post Graduate Trainee (Jr-II), Dept. of Biochemistry, Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra, 442001, India.
  • Professor and Head, Dept. of Biochemistry, Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra, 442001, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Introduction: Diabetes mellitus (DM) is a group of metabolic diseases which if not controlled can cause life threatening complications. Aim: To study serum Lipid Profile and Magnesium level in the hypoglycemic Type II Diabetic subjects. Methodology: Fasting blood glucose (FBG), glycated hemoglobin (HbA1c), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), triglyceride (TG) and Magnesium (Mg) levels were evaluated. Total sample size was 60, which was divided into 30 study group with type II DM having hypoglycemia (blood glucose level <70 mg/dl) who attended the Medicine OPD of AVBRH Hospital and 30 age, sex matched healthy controls included in the study. Results: TC, TG and LDL level were significantly higher in the cases as compared to controls (p<0.0001). Mean value for HbA1c in the study group was 6.94? 0.47, which was significantly higher in the cases as compared to the controls (p<0.0001). Mean value for Magnesium level in the study group was 1.06 ? 0.25, which was significantly lower in the cases as compared to the controls (p<0.0001). HbA1c has significant negative correlation with HDL (p<0.01) and also negative correlation with magnesium. Conclusion: Early detection of serum magnesium and lipid profile abnormalities can minimize the risk for development of diabetic complications in the hypoglycemic type II diabetic patients.

  1. Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association Diabetes Care2009 Jan;?32(Supplement 1):?S62-S67, http://dx.doi.org/10.2337/dc09-S062
  2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes-estimates for the year 2000 and projections for 2030.Diabetes Care.?2004;27(3):1047?53.?[PubMed]
  3. Gupta, V 2002. Diabetes in Elderly Patients. JK Practitioner, 91(4): 258-259..
  4. Yki-Yarvinen, H. 1998. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev. 14(Suppl 1): S45-S50.
  5. Stedman, Thomas Lathrop (December 2005) [1911]. "Stedman's Medical Dictionary" (28th ed.).Baltimore: Lippincott Williams & Wilkins. p. 2100.
  6. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. Aug 5 2009
  7. Mooradian, AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 5:150-159
  8. Windler, E. 2005. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome. Suppl 6: 11-14.
  9. Jamshaid T, Qureshi A. Hyperlipidemia in Diabetics. Pac Postgrad Med J 2002; 13: 159-60.
  10. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 2006; 83: 25-29.
  11. American Diabetes Association. (2003). Implications of the United Kingdom Prospective Diabetes study. Diabetes Care, 26, 28-32.
  12. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus 2002. The AACE system of intensive diabetes self-management-2002 update. Endocrine Pracice, 8, 40-82.
  13. Nathan, D.M., Singer, D.E., Hurxthal, K., and Goodson, J.D. 1984. The clinical information value of the Glycosylated hemoglobin assay. Engl. J. Med. 310:341?346.
  14. Selvin E, Coresh J, Shahar E et al (2005) Glycaemia (hemoglobin A1c) and incident of ischemic stroke: the Atherosclerosis Risk in Communties (ARIC) Study. Lancet Neurol 4:821-826.
  15. American Diabetes Association. 2010. Diagnosis and classification of Diabetes Mellitus. Diabetes Care 33: s6 2-s69.
  16. Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R., 2004. Meta-analysis: glycosy-lated hemoglobin and cardiovascular disease in diabetes mellitus. Intern. Med. 14: 421-431
  17. Kadiyala R, Peter R, Okosieme OE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract. 2010, 64(8):1130-1139
  18. Hatwal A, Gujral AS, Bhatia RP, Agarwal JK, Bajpai HS. Association of hypomagnesemia with diabetic retinopathy. Acta Ophtalmol. 1989; 67:714- 6.
  19. Sasaki S, Oshima T, Matsuura H. Abnormal magnesium status in patients with cardiovascular diseases. ClinSci (Colch). 2000;98:175-81.
  20. Maughan RJ. A simple, rapid method for the determination of glucose, lactate, pyruvate, alanine, 3- hydroxybutyrate and acetoacetate on a single 20-mul blood sample. Clinica Chim Acta 1982;122(2):231-240.
  21. Sullivan DR, KrulJswljk Z, West CV, et al. Determination of serum triglycerides by an accurate enzymatic method not affected by free glycerol. Clin Chem 1985;31(7):1227-1228.
  22. Buccolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19(5):476-482.
  23. Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28(3):514-520.
  24. Erciyas F, Taneli F, Arslan B, et al. Glycemic control oxidative stress and lipid profile in children with type 1 diabetes mellitus. Arch Med Res 2004;35(2):134-140.
  25. Selvin E, Wattanakit K, Steffes MW, et al. HbA1c and peripheral arterial disease in diabetes: the atherosclerosis risk in communities study. Diabetes Care 2006;29(4):877-882.
  26. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the diabetes control and complications trial. Diabetes Care 2002;25(2):275-278.
  27. Khaw KT, Wareham N, Luben R, et al. Glycated hemoglobin, diabetes and mortality in men in Norfolk
  28. cohort of European prospective investigation of cancer and nutrition (EPIC Norfolk). BMJ 2001;322(7277):15- 18.
  29. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996;37(4):693-707.
  30. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010, 340:b5444
  31. Selvin E, Coresh J, Shahar E et al (2005) Glycaemia (HbA1c) and incident of ischemic stroke: the Atherosclerosis Risk in Communties (ARIC) Study. Lancet Neurol 4:821-826.
  32. D. Baxter and P.Webb, ?Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes,?Nature Reviews Drug Discovery, 2009; 8(4):308?320.
  33. Lal J, Vasudev K, Kela AK, Jain SK. Effect of oral magnesium supplementation on lipid profile and blood glucose of patients with type II diabetes mellitus. JAPI. 2003;51:37-42
  34. Rude RK. Magnesium deficiency and diabetes mellitus ? causes and effects. Postgrad Med J. 1992;92:217-24.
  35. Lal J, Vasudev K, Kela AK, Jain SK. Effect of oral magnesium supplementation on lipid profile and
  36. blood glucose of patients with type 2 diabetes mellitus. JAPI. 2003;51:37-42.

[Sarmistha Sarkar and Ajay Meshram. (2017); SERUM LIPID PROFILE AND MAGNESIUM LEVEL IN THE HYPOGLYCEMIC TYPE II DIABETIC SUBJECTS. Int. J. of Adv. Res. 5 (May). 1037-1044] (ISSN 2320-5407). www.journalijar.com

Dr. Sarmistha Sarkar
Post Graduate Trainee (Jr-II), Dept. of Biochemistry, Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra, 442001, India.

DOI:

Article DOI: 10.21474/IJAR01/4213      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4213

Download Full Paper

Download PDF No. of Downloads: 27 | No. of Views: 126